Medication info
Rosucande Tablets 20/32 Milligrams

Rosucande Tablets 20/32 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Gunil Biopharm Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202107116 · Approved 2021.10.25 · Insurance code 073000750

Summary

Main use
Treatment of dyslipidemia, hypertension, and heart failure; inhibition of atherosclerosis; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each ingredient, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into account. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.
Child dose
Adolescents and children aged 18 years or younger: The safety and efficacy have not been established. Adolescents and children aged 18 years or younger: The safety and efficacy have not been established.

Ingredients

Manufacturer
Gunil Biopharm Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, hypertension, and heart failure; inhibition of atherosclerosis; prevention of cardiovascular disease

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • reduced left ventricular ejection fraction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • dysbetalipoproteinemia
  • hypertension
  • low HDL-cholesterol levels
View approved original text

This medication is used for patients who need to take two components, Candesartan Cilexetil and Rosuvastatin together. Candesartan Cilexetil is primarily used for treating essential hypertension and heart failure. It is especially effective in patients with reduced left ventricular function where monotherapy with ACE inhibitors is insufficient or poorly tolerated. Rosuvastatin helps treat hypercholesterolemia and dyslipidemia. It is used as an adjunct when controlled by diet and exercise is not sufficient, reducing the risk of cardiovascular diseases and slowing down the progression of atherosclerosis. It is also used for certain types of familial hypercholesterolemia and dysbetalipoproteinemia. The combination of both components actively manages cardiovascular health by improving blood pressure and serum lipid levels.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each ingredient, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into account. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience of administration.

Child dose

Adolescents and children aged 18 years or younger: The safety and efficacy have not been established. Adolescents and children aged 18 years or younger: The safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. This medication should not be administered to patients with certain liver diseases, severe kidney impairment, myopathy, and hereditary angioedema. Careful monitoring is needed when administering to elderly patients, patients with hyperkalemia, and those with mild to moderate liver impairment; liver function and muscle condition should be regularly tested. The medication can cause serious muscle adverse effects such as myalgia, myopathy, and rarely, rhabdomyolysis, so consult a doctor immediately if symptoms like muscle pain or weakness occur. Additionally, as this medication can elevate liver enzyme levels, it is important to undergo liver function tests before and during treatment. It may result in drug interactions when combined with other antihypertensives or specific lipid-lowering agents, potassium-sparing diuretics, etc., and should be taken under a doctor's guidance. Pregnant or breastfeeding women should not use this medication; women of childbearing potential should use appropriate contraception. Safety and efficacy in children have not been established, so use is not recommended for this age group. In case of overdose, symptoms such as hypotension and dizziness may occur; immediate medical assistance should be sought, and there is no specific antidote. Caution should be exercised when driving or operating machinery as dizziness due to blood pressure lowering may occur. Finally, this medication should be stored out of reach of children, and it is safe not to transfer it from its original container to another container.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, orthostatic dizziness, xanthoma, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, oculobulbar weakness, hypotension, hyperkalemia, renal impairment, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, leukopenia, neutropenia, agranulocytosis, hyperkalemia, hyponatremia, hypoglycemia, weakness, hunger, cold sweat, hand tremor, decreased concentration, convulsions, altered consciousness, pneumonia, intestinal vascular edema, increased liver enzyme levels, hepatitis, elevated AST, elevated ALT, elevated γ-GTP, jaundice, vascular edema, rhabdomyolysis, arthralgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, increased tension, syncope, facial flushing, weight gain, facial edema, thirst, sleep disorder, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, nausea, abdominal pain, pancreatitis, joint pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container away from air and moisture, preferably at room temperature between 1 degree and 30 degrees Celsius. Proper storage will safely maintain the medication's efficacy.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.